Cargando...
Targeted treatments for multiple myeloma: specific role of carfilzomib
Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Ph...
Guardado en:
| Publicado en: | Pharmgenomics Pers Med |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4325627/ https://ncbi.nlm.nih.gov/pubmed/25691814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S39085 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|